Vasculitis & polymyalgia rheumatica
Glucocorticoids vs glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis without poor-prognosis factors: a target trial emulation study
Authors' conclusion
This study shows that the adjunction of CYC to GCs does not reduce the risk of relapse in patients with EGPA and no poor-prognosis factors.
Study context
- Population
- Patients with newly diagnosed eosinophilic granulomatosis with polyangiitis (EGPA), Five Factor Score (FFS) = 0 at diagnosis, treated with glucocorticoids (GCs) or GCs plus CYC
- Participants
- 250 patients
- Exposure
- GCs plus CYC vs GCs alone
- GCs + CYCn = 73
- GCs alonen = 177reference
- Outcome
- Overall relapse
- Follow-up
- 12 months
Methodological detailsEuropean multicentre retrospective study, inverse probability of treatment weighting
- European multicentre retrospective study
- Inverse probability of treatment weighting
Main finding
As reported in the abstract
- After adjustment, no reduction in the risk of overall relapse between the two treatment groups
Observational data: associations, not effects.
Further findings
Overall relapse in patients with severe manifestations (subgroup)
- Similar results (no reduction in relapse risk)
Original publication
Glucocorticoids vs glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis without poor-prognosis factors: a target trial emulation study. Rheumatology (Oxford). Published 24 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →